Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2021—PixCell Medical (Yokne’am Illit, Israel) announced it has opened a U.S. subsidiary in the Denver metropolitan area. The new office aims to increase logistical and commercial support for the company’s U.S. clients and will handle order fulfilment across the country as well as provide additional clinical and technical support to customers.
December 2021—Sysmex introduced its TH-11 Urine Sample Decapper Unit, which is designed to be used in conjunction with the Sysmex UN-Series Automated Urinalysis Solution. The unit is intended to eliminate manual decapping work, which can reduce workplace repetitive injuries, streamline work processes, and reduce exposure to biological hazards. The TH-11 comes in desktop or wagon modules.
December 2021—Lighthouse Lab Services announced that the FDA has granted emergency use authorization for its CovidNow SARS-CoV-2 assay kit. The EUA covers use for symptomatic and asymptomatic patients with a provider’s order.
December 2021—Roche has launched the Avenio Tumor Tissue Comprehensive Genomic Profiling Kit, complementing the current CGP portfolio offered by Roche and Foundation Medicine.
December 2021—The results of Olympus’ ongoing joint research program to create an AI-based pathology diagnostic tool were announced at the Japan Society of Digital Pathology Study annual meeting. The AI tool was able to achieve 100 percent sensitivity and 50 percent or higher specificity for all gastric biopsy pathology specimens analyzed from the six facilities participating in the study.
December 2021—Bio-Rad announced its Exact Diagnostics RP Positive Run Control for syndromic respiratory panels is now available with inactivated whole virus for SARS-CoV-2. The unassayed external quality control contains 23 respiratory analytes in one vial and is intended to monitor the performance of clinical respiratory assays. The control is a combination of whole, intact virus and bacteria that have been heated or chemically inactivated and synthetic RNA transcripts.
December 2021—LumiraDx announced that the FDA’s emergency use authorization for its SARS-CoV-2 antigen test has been expanded to include screening of asymptomatic individuals. This claim builds on its existing claim that covers use of the test in individuals suspected of having COVID-19 by their health care provider within 12 days of symptom onset. The test received EUA in August 2020.
December 2021—Microbix Biosystems has expanded its portfolio of quality assessment products to include controls that support PCR tests for four major variants of concern of SARS-CoV-2.
November 2021—Verichem Laboratories offers ready-to-use, liquid-stable clinical reference materials for microprotein testing, suitable for use with turbidimetric and colorimetric test methods. The products are intended for the calibration and calibration verification of clinical systems testing for total protein and albumin in urine and cerebral spinal fluid. The kit contains a five-level set with 15 mL of material at each level and provides 10 individual certified concentrations in an azide-free format, incorporating human protein components for optimum reactivity.
November 2021—Labcon North America, a wholly owned subsidiary of Helena Laboratories, has announced a $59.3 million contract award from the U.S. Department of Defense in coordination with the U.S. Department of Health and Human Services.
